NEWS: We just received funding for coordinating a large preclinical development study, incl biomarker investigations, "Antifibrotix", joint with IBMT and UAK (Augenklinik) We also just received funding for preparing the development of senotherapies. We also expect to coordinate an in-depth biomarker study of cellular senescence.

More information will be posted soon.


The core interest of the Bioinformatics is the investigation of intervention effects using gene expression (next-generation sequencing) data.
We wish to discover the healthspan pathways triggered by interventions proposed to enable healthy ageing (EU Horizon 2020 project). We predicted which drugs may be repositioned to inhibit fibrosis after glaukoma surgery (BMBF validation research project), and validated the top-ranking compound in vitro.
Also, we work with Leukemia, Parkinson, and Alzheimer data, among others.

The Bioinformatics is composed of the following groups:

  • Medical Bioinformatics (Möller, Fuellen), focussed on intervention effects,
  • Junior Research Group Integrative OMICS Analyses (Hamed),
  • Next-generation sequencing data (Barrantes).

The mission of the Biostatistics department can be found here.

EFRE-geförderte Ausstattung

With all the best wishes for a long healthspan
Georg Fuellen, Institute Director


Prof. Dr. Georg Füllen
0381 494 7360
0381 494 7203


Ms Brauer
0381 494 7361
0381 494 7203


Institut für Biostatistik und Informatik in Medizin und Alternsforschung (IBIMA)
Ernst-Heydemann-Str. 8
18057 Rostock